Last Updated: August 25, 2026

CLINICAL TRIALS PROFILE FOR OPICAPONE

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Opicapone

Subscribe to access the full database, or Start Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01227655 ↗	Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.	Completed	Bial - Portela C S.A.	Phase 3	2011-03-01	Parkinson's disease (PD) is a neurodegenerative disorder of unknown aetiology with an estimated incidence of 4.5-16/100,000 persons/year. BIA 9-1067 is currently being developed by BIAL (Portela & Cª,S.A.) to be used in addition to L-DOPA (Levodopa) /carbidopa or L-DOPA (Levodopa) / preparations in PD patients. Promising results have been obtained for BIA 9-1067 in previous studies.
NCT01515891 ↗	Absorption, Distribution, Metabolism and Excretion of [14C]-Labeled BIA 9-1067 and Metabolites	Completed	Bial - Portela C S.A.	Phase 1	2009-05-01	To determine the absorption, metabolism and excretion of BIA 9-1067.
NCT01851850 ↗	Continuation Treatment Protocol for Patient Who Participated in the BIA 9-1067-302 Clinical Trial	Completed	Rabin Medical Center	Phase 3	2013-05-01	The purpose of the study is to extend the use of opicapone 25 or 50mg once per day by subjects who participated in the BIA 9-1067-302 clinical trial according form 4a for additional three years.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for Opicapone

Condition Name

Chart
Table

Condition Name for Opicapone
Intervention	Trials
Parkinson Disease	12
Parkinson's Disease	4
Parkinson	2
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for Opicapone
Intervention	Trials
Parkinson Disease	19
Sleep Wake Disorders	1
Parasomnias	1
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for Opicapone

Trials by Country

Map
Table

Trials by Country for Opicapone
Location	Trials
United Kingdom	3
United States	2
Germany	2
Portugal	2
France	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for Opicapone
Location	Trials
Michigan	1
California	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for Opicapone

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for Opicapone
Clinical Trial Phase	Trials
Phase 4	5
Phase 3	3
Phase 1	12
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for Opicapone
Clinical Trial Phase	Trials
Completed	16
Recruiting	4
Not yet recruiting	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Opicapone

Sponsor Name

Chart
Table

Sponsor Name for Opicapone
Sponsor	Trials
Bial - Portela C S.A.	17
Rabin Medical Center	1
Neurocrine Biosciences	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for Opicapone
Sponsor	Trials
Industry	19
Other	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.